Chai Hong Rim1, Young Kim2, Chul Yong Kim3, Won Sup Yoon1, Dae Sik Yang4. 1. a Department of Radiation Oncology , Ansan Hospital Korea University Medical College , Ansan , Republic of Korea. 2. b Division of Pulmonary Sleep and Critical Care Medicine, Department of Internal Medicine , Ansan Hospital Korea University Medical College , Ansan , Republic of Korea. 3. c Department of Radiation Oncology , Anam Hospital Korea University Medical College , Seoul , Republic of Korea. 4. d Department of Radiation Oncology , Guro Hospital Korea University Medical College , Seoul , Republic of Korea.
Abstract
INTRODUCTION: Ultra-central (UC) tumors, which are generally defined as tumors directly abutting the proximal bronchial tree, are difficult to treat with stereotactic body radiotherapy (SBRT) owing to possible serious complications. This systemic review and meta-analysis analyzed the early experiences and evaluated the efficacy and feasibility of SBRT for UC tumors. METHODS AND MATERIALS: The present study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Systemic searches of the EMBASE, PubMed, MEDLINE, and Cochrane library electronic databases were performed. The primary endpoints were two-year local control (LC), overall survival (OS), and grade ≥3 complication rates. A random-effects model was used to determine the pooled rates of the primary endpoints. Grade 5 complications were descriptively assessed. RESULTS: Nine studies involving 291 patients with UC tumors who underwent SBRT were included. The pooled two-year LC, two-year OS, and grade ≥3 complication rates were 96.7% (95% confidence interval [CI]: 91.0-98.9), 57.7% (95% CI: 32.0-79.8), and 23.2% (95% CI: 11.8-40.5), respectively. The incidence of grade 5 complication was 0-22% and was 0% in three of eight available studies. Hemorrhage (68.2%) was the commonest fatal complication. The risk factors for fatal hemoptysis included anticoagulant use, excessive maximum irradiation dose, endobronchial involvement, squamous histology, and bevacizumab exposure. CONCLUSIONS: SBRT for UC tumors confers efficient LC, although the risk of complications was not negligible. Control of possible risk factors of hemorrhage and dose optimization through further studies are warranted.
INTRODUCTION: Ultra-central (UC) tumors, which are generally defined as tumors directly abutting the proximal bronchial tree, are difficult to treat with stereotactic body radiotherapy (SBRT) owing to possible serious complications. This systemic review and meta-analysis analyzed the early experiences and evaluated the efficacy and feasibility of SBRT for UC tumors. METHODS AND MATERIALS: The present study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Systemic searches of the EMBASE, PubMed, MEDLINE, and Cochrane library electronic databases were performed. The primary endpoints were two-year local control (LC), overall survival (OS), and grade ≥3 complication rates. A random-effects model was used to determine the pooled rates of the primary endpoints. Grade 5 complications were descriptively assessed. RESULTS: Nine studies involving 291 patients with UC tumors who underwent SBRT were included. The pooled two-year LC, two-year OS, and grade ≥3 complication rates were 96.7% (95% confidence interval [CI]: 91.0-98.9), 57.7% (95% CI: 32.0-79.8), and 23.2% (95% CI: 11.8-40.5), respectively. The incidence of grade 5 complication was 0-22% and was 0% in three of eight available studies. Hemorrhage (68.2%) was the commonest fatal complication. The risk factors for fatal hemoptysis included anticoagulant use, excessive maximum irradiation dose, endobronchial involvement, squamous histology, and bevacizumab exposure. CONCLUSIONS: SBRT for UC tumors confers efficient LC, although the risk of complications was not negligible. Control of possible risk factors of hemorrhage and dose optimization through further studies are warranted.
Entities:
Keywords:
Stereotactic body radiotherapy; central tumor; feasibility; lung cancer; ultra-central tumor
Authors: Rosie Cooke; Philip Camilleri; Kwun-Ye Chu; Séan M O'Cathail; Maxwell Robinson; Frank Van Den Heuvel; Maria A Hawkins Journal: Tech Innov Patient Support Radiat Oncol Date: 2020-02-17
Authors: Matthew Chan; David Palma; Aisling Barry; Andrew Hope; Richard Moore; Melissa O'Neil; Janet Papadakos; Devin Schellenberg; Tony Tadic; C Jillian Tsai; Meredith Giuliani Journal: Adv Radiat Oncol Date: 2020-06-18
Authors: Sebastian Regnery; Carolin Buchele; Fabian Weykamp; Moritz Pohl; Philipp Hoegen; Tanja Eichkorn; Thomas Held; Jonas Ristau; Carolin Rippke; Laila König; Michael Thomas; Hauke Winter; Sebastian Adeberg; Jürgen Debus; Sebastian Klüter; Juliane Hörner-Rieber Journal: Front Oncol Date: 2022-01-11 Impact factor: 6.244